Delineating the relationship between circulating osteoprotegerin and bone health in women with a pathogenic variant in

Osteoprotegerin (OPG) plays an important role in the inhibition of osteoclast formation and bone resorption. Studies have reported lower OPG levels among women with a pathogenic variant (mutation) in the Women with a blood sample and clinical data were included in this analysis. An enzyme-linked immunosorbent assay (ELISA) was used to quantify serum OPG (pg/mL) and the 10-year risk of Among 701 women with a Our findings suggest that women with inherently lower OPG may be at risk of lower BMD, the gold standard marker of bone disease. Due to the young age of our cohort, on-going studies are warranted to re-evaluate the association between OPG and FRAX in

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

All the authors named on this paper declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors have seen and approved the final version of the manuscript being submitted. They warrant that the article is the authors' original work, has not received prior publication and is not under consideration for publication elsewhere.